04
Mar
2010
Posted in I - Series B, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology
Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.
04
Mar
2010
01
Mar
2010
Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform
F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.
11
Feb
2010
Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Oncology, X - Therapeutic Platform
arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]
02
Feb
2010
22
Jan
2010
20
Jan
2010
17
Jan
2010
Posted in Q - 4Q09, R - NORTH EAST, X - Antibody, X - Biosimilars, X - Cytokine, X - Therapeutic Platform, XX - MA
Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $12M Series X financing bringing the total round to $45M. Participants include New Leaf Venture Partners, [...]
25
Nov
2009
Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Antibody, X - Autoimmune, X - Inflammation, XX - MA
Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.
02
Nov
2009
Posted in I - Series A, Q - 3Q09, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology
PharmAbcine (South Korea) a development-stage biopharma company focused on the development of monoclonal antibodies for cancer and inflammatory disease, closed a $6M Series A financing. Participants include OrbiMed, Novartis Venture Fund, Green Cross, Tong Yang Venture Capital and Saehan Venture Fund.